Use of antiarrhythmic drugs in elderly patients

被引:28
作者
Lee, Hon-Chi [1 ]
Huang, Kristin T. L. [2 ]
Shen, Win-Kuang [3 ]
机构
[1] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Scottsdale, AZ 85259 USA
关键词
aging; antiarrhythmic drugs; pharmacokinetics; pharmacodynamics; polypharmacy; cardiac electrophysiology; ion channels; BETA-ADRENERGIC RESPONSIVENESS; ACTION-POTENTIAL PROLONGATION; AGE-ASSOCIATED CHANGES; SUDDEN CARDIAC DEATH; OLDER-ADULTS; HEART-RATE; ORTHOSTATIC HYPOTENSION; BLEEDING COMPLICATIONS; CREATININE CLEARANCE; ATRIAL-FIBRILLATION;
D O I
10.3724/SP.J.1263.2011.00184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca2+ overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.
引用
收藏
页码:184 / 194
页数:11
相关论文
共 103 条
  • [1] Effcet of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide
    Abel, S
    Nichols, DJ
    Brearley, CJ
    Eve, MD
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (01) : 64 - 71
  • [2] DISOPYRAMIDE-INDUCED URINARY RETENTION
    ALVES, LE
    ROSE, EP
    CAHILL, TB
    HAI, HA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (10) : 2099 - 2099
  • [3] [Anonymous], 2009, World Population Prospects: The 2008 Revision
  • [4] Review on Pharmacokinetics and Pharmacodynamics and the Aging Kidney
    Aymanns, Christian
    Keller, Frieder
    Maus, Sebastian
    Hartmann, Bertram
    Czock, David
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (02): : 314 - 327
  • [5] Sodium current function in adult and aged canine atrial cells
    Baba, Shigeo
    Dun, Wen
    Hirose, Masanori
    Boyden, Penelope A.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (02): : H756 - H761
  • [6] Interactions between grapefruit juice and cardiovascular drugs
    Bailey D.G.
    Dresser G.K.
    [J]. American Journal of Cardiovascular Drugs, 2004, 4 (5) : 281 - 297
  • [8] A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial
    Beyth, RJ
    Quinn, L
    Landefeld, CS
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 687 - 695
  • [9] BONOW RO, 2011, BRAUNWALDS HEART DIS, P1727
  • [10] Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001